CN
Product Service Diagnosis and Treatment BGI Lung Cancer Genetic Test
Clinical overview of lung cancer
Lung cancer is the leading malignant cancer in terms of worldwide incidence and mortality. According to the World Cancer Report 2020, there were 2.1 million new cases of lung cancer and 1.8 million deaths from lung cancer in 2020. The prevention of lung cancer is challenging.

The genes currently recommended in the NCCN Guidelines for Non-Small Cell Lung Cancer, and the corresponding FDA- and NMPA-approved targeted drugs are shown in the chart below.
In addition, a number of new drugs are currently in clinical trials.
BGI Lung Cancer Genetic Test
The test is designed based on BGI's own high-throughput sequencing platform. It can reveal the relationship between multiple targeted drugs and genetic variants using biopsies from lung cancer patients as samples, providing reference for precision targeted-therapy for patients with non-small cell lung cancer.
Product features
Scope of the test
Suitable for

    Patients with non-small cell lung cancer, who can have or have had a biopsy sample and that are candidates for undergoing targeted therapy

Sample requirements

    FFPE biopsy, pleural effusion and ascites

Customer Service:

+1 866 301 0097

Service Time:7*24

Language:English

E-mail: info@bgi.com

Copyright © BGI 2022. All Rights Reserved. Guangdong ICP Registration No. 16021117